Phase 1b/2a Open-Label, Multiple-Dose, Dose-Escalation Study To Evaluate The Safety and Tolerability Of Intravenous Infusion Of SNS01-T In Patients With Relapsed Or Refractory Multiple Myeloma, Mantle Cell Lymphoma, Or Diffuse Large B Cell Lymphoma

被引：3
|
作者：
Lust, John A.
Barranco, Charles
Usmani, Saad Z.
van Rhee, Frits
Hamadani, Mehdi
Thompson, John
Taylor, Catherine A.
Dondero, Richard
Browne, Leslie J.
Siegel, David
Bensinger, William I.
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
10.1182/blood.V122.21.1950.1950
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1950
引用
收藏
页数：2
相关论文
共 50 条
  • [21] A Phase 1/1b Open-Label, Multicenter, Two- Part Study of SETD2 Inhibitor EZM0414 in Patients with Relapsed/Refractory Multiple Myeloma or Diffuse Large B-Cell Lymphoma
    Richardson, Paul G.
    Niesvizky, Ruben
    Yang, Jay
    Yadav, Neelu
    Hsu, Helen
    Flowers, Christopher R.
    BLOOD, 2021, 138
  • [22] Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study
    Amorim, Sandy
    Stathis, Anastasios
    Gleeson, Mary
    Iyengar, Sunil
    Magarotto, Valeria
    Leleu, Xavier
    Morschhauser, Franck
    Karlin, Lionel
    Broussais, Florence
    Rezai, Keyvan
    Herait, Patrice
    Kahatt, Carmen
    Lokiec, Francois
    Salles, Gilles
    Facon, Thierry
    Palumbo, Antonio
    Cunningham, David
    Zucca, Emanuele
    Thieblemont, Catherine
    LANCET HAEMATOLOGY, 2016, 3 (04): : E196 - E204
  • [23] Phase I dose escalation of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and follicular lymphoma (FL).
    Batlevi, Connie Lee
    Hamlin, Paul A.
    Matasar, Matthew J.
    Horwitz, Steven M.
    Gerecitano, John F.
    Moskowitz, Craig H.
    Straus, David J.
    Zelenetz, Andrew David
    Drullinsky, Pamela
    Copeland, Amanda
    Ahsanuddin, Salma
    Callan, Devin
    Freidin, Benjamin
    Porzio, Robert
    Dang, Thu Oanh
    Ni, Ai
    Rademaker, Jurgen
    Schoder, Heiko
    Dogan, Ahmet
    Younes, Anas
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [24] A Phase 1/2 Open-label, Multiple-dose, Dose-escalation Clinical Trial of the Safety and Tolerability of GTX-102 in Pediatric Patients with Angelman Syndrome
    Sell, E.
    Servais, L.
    Harijan, P.
    Stromatt, S.
    Brandabur, M.
    Berry-Kravis, E.
    ANNALS OF NEUROLOGY, 2022, 92 : S163 - S163
  • [25] Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma part 2 of the open-label, multicenter, dose-escalation phase Ib study (PAVO)
    San-Miguel, Jesus
    Usmani, Saad Z.
    Mateos, Maria-Victoria
    van de Donk, Niels W. C. J.
    Kaufman, Jonathan L.
    Moreau, Philippe
    Oriol, Albert
    Plesner, Torben
    Benboubker, Lotfi
    Liu, Kevin
    Hellemans, Peter
    Masterson, Tara
    Clemens, Pamela L.
    Luo, Man
    Farnsworth, Andrew
    Nahi, Hareth
    Chari, Ajai
    HAEMATOLOGICA, 2021, 106 (06) : 1725 - 1732
  • [26] Phase 1b Dose-finding Study of Venetoclax With Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
    Petrillo, Alessandra
    Ip, Andrew
    Della Pia, Alexandra
    Gill, Sarvainder
    Zenreich, Joshua
    Gutierrez, Martin
    McNeill, Ann
    Feldman, Tatyana
    Leslie, Lori A.
    Goy, Andre
    HEMASPHERE, 2022, 6 (06):
  • [27] Open-Label Phase 2 Study Of The Bispecific T-Cell Engager (BiTE®) Blinatumomab In Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Viardot, Andreas
    Goebeler, Mariele
    Pfreundschuh, Michael
    Adrian, Nicole
    Libicher, Martin
    Degenhard, Evelyn
    Stieglmaier, Julia
    Zhang, Alicia
    Nagorsen, Dirk
    Bargou, Ralf C.
    BLOOD, 2013, 122 (21)
  • [28] Phase 1b/2a Study of AZD4573 (CDK9i) and Acalabrutinib in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL): Results from Dose-Escalation
    Strati, Paolo
    Kim, Tae Min
    Danilov, Alexey, V
    Cheah, Chan Y.
    Yoon, Dok Hyun
    Jurczak, Wojciech
    Sharma, Shringi
    Yoon, Jeong Lim
    Arduini, Serena
    Saeh, Jamal
    Olsson, Richard F.
    Gregory, Gareth
    BLOOD, 2022, 140 : 6656 - 6658
  • [29] Subcutaneous daratumumab (DARA) in patients (Pts) with relapsed or refractory multiple myeloma (RRMM): Part 2 update of the open-label, multicenter, dose escalation phase 1b study (PAVO).
    Chari, Ajai
    Usmani, Saad Zafar
    Mateos, Maria-Victoria
    Van De Donk, Niels
    Kaufman, Jonathan L.
    Moreau, Philippe
    Rocafiguera, Albert Oriol
    Plesner, Torben
    Benboubker, Lotfi
    Liu, Kevin
    Hellemans, Peter
    Masterson, Tara J.
    Clemens, Pamela L.
    Farnsworth, Andrew
    Nahi, Hareth
    San-Miguel, Jesus
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [30] A Phase 1b Study to Evaluate the Safety and Efficacy of Durvalumab in CombinationWith Tremelimumab or Danvatirsen in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Ribrag, Vincent
    Lee, Seung Tae
    Rizzieri, David
    Dyer, Martin J. S.
    Fayad, Luis
    Kurzrock, Razelle
    Andritsos, Leslie
    Bouabdallah, Reda
    Hayat, Amjad
    Bacon, Larry
    Jiang, Yu
    Miah, Kowser
    Delafont, Bruno
    Hamid, Oday
    Anyanwu, Stephanie
    Martinez, Pablo
    Hess, Brian
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (05): : 309 - +
12345